232 related articles for article (PubMed ID: 23751588)
1. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Feng JH; Xu XJ; Tang YM
Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
[No Abstract] [Full Text] [Related]
2. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
[No Abstract] [Full Text] [Related]
3. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
4. Combining flow cytometry and
Guolo F; Minetto P; Clavio M; Miglino M; Galaverna F; Raiola AM; Di Grazia C; Colombo N; Pozzi S; Ibatici A; Bagnasco S; Guardo D; Kunkl A; Ballerini F; Ghiggi C; Lemoli RM; Gobbi M; Bacigalupo A
Haematologica; 2017 Sep; 102(9):e348-e351. PubMed ID: 28495917
[No Abstract] [Full Text] [Related]
5. Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia.
Xu XJ; Feng JH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2013 Feb; 37(2):134-8. PubMed ID: 23199895
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
7. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
Hokland P; Cotter F
Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
[No Abstract] [Full Text] [Related]
8. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Stone RM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
Miyazaki T; Fujita H; Fujimaki K; Hosoyama T; Watanabe R; Tachibana T; Fujita A; Matsumoto K; Tanaka M; Koharazawa H; Taguchi J; Tomita N; Sakai R; Fujisawa S; Kanamori H; Ishigatsubo Y
Leuk Res; 2012 Aug; 36(8):998-1003. PubMed ID: 22551655
[TBL] [Abstract][Full Text] [Related]
10. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
11. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of minimal residual disease detection in childhood acute leukemia].
Cheng YQ; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2018 May; 20(5):416-420. PubMed ID: 29764581
[TBL] [Abstract][Full Text] [Related]
13. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
14. Effect of processing time on analysis of rare event in minimal residual disease study.
Rai S; Bhardwaj U; Singh S; Misra A
Indian J Pathol Microbiol; 2017; 60(3):449-451. PubMed ID: 28937402
[No Abstract] [Full Text] [Related]
15. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
18. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
20. Progress of minimal residual disease studies in childhood acute leukemia.
Campana D
Curr Hematol Malig Rep; 2010 Jul; 5(3):169-76. PubMed ID: 20467922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]